Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Aug 16;224(8):e70253. doi: 10.5694/mja2.70253

Estimating Eligibility for GLP‐1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross‐Sectional Analysis of National Health Survey Data

Jasmin Castrillon 1, Chris Schilling 1, Sharmala Thuraisingam 1, Michael W Hii 1,2, Priya Sumithran 3,4, Peter F Choong 1, Michelle M Dowsey 1, Cade Shadbolt 1,✉
PMCID: PMC13477643  PMID: 42604458

ABSTRACT

Objective

To estimate population‐level eligibility for glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) medications among adults in Australia, according to Therapeutic Goods Administration‐approved indications for chronic weight management and secondary prevention of cardiovascular disease in individuals with overweight or obesity.

Study Type

Cross‐sectional analysis of data from the Australian Bureau of Statistics 2022 National Health Survey.

Setting, Participants

Non‐pregnant adults aged ≥ 18 years who were residents of Australia living in a private dwelling.

Main Outcome Measures

Total number of adults eligible for GLP‐1RA medications according to approved indications for chronic weight management and secondary prevention of cardiovascular disease in individuals with overweight or obesity, across subgroups defined by body mass index, weight‐related comorbidities and/or sociodemographic factors.

Results

Overall, 39.7% (95% confidence interval [CI], 38.4%–41.0%) of adults were eligible for GLP‐1RA use for chronic weight management, accounting for 7.8 million (95% CI, 7.6–8.1 million) individuals. Among those eligible, 2.9 million (95% CI, 2.7–3.1 million) adults had no weight‐related comorbidities, 3.3 million (95% CI, 3.1–3.4 million) adults had one weight‐related comorbidity and 1.7 million (95% CI, 1.6–1.8 million) adults had at least two weight‐related comorbidities. The proportion of adults eligible under this indication varied across clinical and sociodemographic factors. Among those eligible under the chronic weight management indication, up to 338.9 thousand (95% CI, 271.3–406.5 thousand) adults also met the indication criteria for secondary prevention of cardiovascular disease.

Conclusion

About 7.8 million Australian adults are eligible to access GLP‐1RAs for chronic weight management, with up to 338.9 thousand adults also qualifying according to the indication for established cardiovascular disease. This study provides a valuable reference for policymakers to understand the number of adults in Australia who may access GLP‐1RA medications based on approved indication criteria and under various coverage scenarios.

Keywords: Cardiovascular disease, Glucagon‐like peptide‐1 receptor agonist, obesity

Plain Language Summary

The Known: Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) medications have established benefits for both management of overweight/obesity and the secondary prevention of cardiovascular disease.

The New: This study provides the first estimates of the number of adults in Australia who are eligible for treatment with GLP‐1RAs across Therapeutic Goods Administration‐approved indications for chronic weight management and secondary prevention of cardiovascular disease, alongside estimates of eligibility under coverage scenarios based on body mass index and comorbidities.

The Implications: Our findings offer a policy‐relevant reference of the number of adults who could benefit from treatment, supporting advocacy, coverage decisions and healthcare system planning.

1. Introduction

Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) medications have received regulatory approval by the Therapeutic Goods Administration (TGA) in Australia for indications including type 2 diabetes, chronic weight management and the secondary prevention of cardiovascular disease [1, 2, 3, 4]. While TGA approval allows a medication to be marketed in Australia, the Pharmaceutical Benefits Scheme (PBS) determines whether it is subsidised by the government. The PBS currently subsidises semaglutide and dulaglutide for individuals with type 2 diabetes that has not adequately responded to other antihyperglycemic medications including sodium‐glucose cotransporter 2 inhibitors [5, 6]. No GLP‐1RA medications are currently subsidised by the PBS for obesity or secondary prevention of cardiovascular disease. However, based on demonstration of cardiovascular benefits [7], the Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended subsidising semaglutide for adults with established cardiovascular disease and obesity, indicating that subsidies may be limited to individuals with a body mass index (BMI) of 35 kg/m2 or higher due to the cost of the medication [8].

Despite ongoing national and international debate about appropriate coverage of GLP‐1RA medications for indications beyond diabetes [9, 10], the total number of adults in Australia who are currently eligible to use these medications for chronic weight management or secondary prevention of cardiovascular disease in individuals with overweight or obesity remains unclear. In a recent international study, 27% of adults across 99 countries (not including Australia) were eligible to use GLP‐1RA medications according to their approved indication for obesity [11]. Notably, these estimates varied widely even between high‐income countries, further highlighting the need for reliable local estimates. In this study, we aim to provide nationally representative estimates of the total number of adults currently eligible according to TGA‐approved indications for GLP‐1RAs for chronic weight management and secondary prevention of established cardiovascular disease in individuals with overweight or obesity. We also aim to estimate the numbers and proportions of adults who are eligible for these medications across subpopulations defined by key sociodemographic and clinical characteristics, and estimate the numbers of adults who may be eligible for access to these medications under a range of coverage scenarios.

2. Methods

This study involved a cross‐sectional analysis of data from the Australian Bureau of Statistics 2022 National Health Survey [12]. We report this study in accordance with the Preferred Reporting Items for Complex Sample Survey Analysis (Supporting Information S1) [13].

2.1. Data Source and Sample Selection

Our sample included all non‐pregnant adults aged 18 years or older. Pregnant adults were excluded due to both the absence of accurate BMI measurements and pregnancy being an explicit contraindication to GLP‐1RA use. The National Health Survey collects data from a sample of randomly selected households across Australia [14]. Survey respondents are interviewed to collect information about sociodemographics, health conditions and physical measurements [14]. The Australian Bureau of Statistics provides calibrated person‐level survey weights to enable unbiased nationally representative estimates of its target population of all usual residents in Australia living in private dwellings, which account for both the sampling design and non‐response (43.3%) [14].

2.2. Identification of Eligible Individuals

Individuals who are eligible for GLP‐1RA medications for chronic weight management and secondary prevention of cardiovascular disease in adults with overweight or obesity were identified based on the approved indications outlined by the TGA. All survey variables and measures used to address each eligibility criterion are described in Table S1.

2.3. Chronic Weight Management

Currently, semaglutide and tirzepatide are the only available medications with regulatory approval for chronic weight management [1, 3]. We defined eligible individuals as adults with a BMI ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 and < 30 kg/m2 and at least one weight‐related comorbidity, including hypertension, dyslipidaemia, cardiovascular disease or type 2 diabetes. As weight‐related comorbidities were not clearly defined in the TGA approval, we limited these conditions to those used to determine eligibility in the key Phase 3 trials of these medications [15, 16, 17, 18]. Obstructive sleep apnoea was not included in our analysis, as the National Health Survey does not collect information on this condition. Consistent with the eligibility criteria of the key trials, we employed the broad criteria developed by the National Health Survey (e.g., angina, myocardial infarction, ischaemic heart diseases, stroke, other cerebrovascular diseases, oedema, heart failure and other vascular disorders) to define cardiovascular disease.

2.4. Secondary Prevention of Cardiovascular Disease

Currently, semaglutide is the only GLP‐1RA medication approved in Australia for secondary prevention of cardiovascular disease in adults with overweight or obesity [1]. We defined individuals as eligible according to this indication if they were adults with established cardiovascular disease and a BMI ≥ 27 kg/m2, without diabetes. Established cardiovascular disease was defined in the clinical trial used to support this indication as having had a prior myocardial infarction, having had a prior stroke or having symptomatic peripheral arterial disease [7]. Our primary definition of ‘confirmed established cardiovascular disease’ included only individuals who had a prior stroke and/or myocardial infarction, which were conditions specifically recorded by the survey. However, the National Health Survey does not provide specific information on diagnoses of symptomatic peripheral arterial disease, which is grouped within the broader category of diseases of arteries, arterioles and capillaries (International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes I70–I79). To examine the impact of our more conservative primary definition, we classified individuals as having ‘possible established cardiovascular disease’ if they reported a condition coded to the broader category of diseases of arteries, arterioles and capillaries without meeting our primary definition of established cardiovascular disease (i.e., no prior stroke or myocardial infarction).

2.5. Statistical Analysis

We estimated the total numbers of non‐pregnant adults in Australia who were eligible and not eligible for GLP‐1RAs for chronic weight management across several sociodemographic and clinical characteristics, including age, sex, education (secondary or below, certificate/diploma, university‐level), weight‐related comorbidities and household income quintiles. We then estimated the proportion of individuals within each of these subpopulations who were eligible for GLP‐1RAs for chronic weight management. To examine population‐level eligibility under a range of different coverage scenarios, we calculated the total numbers of adults in Australia eligible for GLP‐1RAs for chronic weight management across subgroups defined by both BMI categories and numbers of weight‐related comorbidities. BMI and comorbidity groupings were informed by recent PBAC recommendations [8] and international coverage policies [9], which limit eligibility using similar cut‐points. Among those eligible for chronic weight management, we then estimated the total numbers of adults eligible and not eligible for GLP‐1RAs for secondary prevention of established cardiovascular disease across subgroups defined by BMI categories. Given that the PBS subsidises semaglutide and dulaglutide for some adults with type 2 diabetes in Australia, we conducted a sensitivity analysis to examine the numbers of adults without type 2 diabetes who are eligible for GLP‐1RA use for chronic weight management across subgroups defined by BMI categories and numbers of weight‐related comorbidities.

All analyses used person‐level survey weights to derive nationally representative estimates, with jackknife replicate weights used to estimate corresponding 95% confidence intervals [14, 19]. All data were analysed in the Australian Bureau of Statistics DataLab using Stata 18.0 (StataCorp), accounting for complex survey design and using the ‘subpop’ and ‘over’ commands for subpopulation analyses.

2.6. Ethics Statement

This study was approved by the University of Melbourne Human Research Ethics Committee (reference number: 2026‐32594‐78480‐7).

3. Results

In total, 13,039 individuals were included in the unweighted sample, representing 19.7 million (95% CI, 19.7–19.7 million) non‐pregnant adults (Table 1). After weighting, an estimated 39.7% (95% CI, 38.4%–41.0%) of adults were eligible for GLP‐1RA use for chronic weight management, accounting for 7.8 million (95% CI, 7.6–8.1 million) adults. The proportion of adults eligible for GLP‐1RA use for chronic weight management varied across clinical and sociodemographic factors. Of note, a greater proportion of adults was eligible among those with the lowest household incomes (44.4%; 95% CI, 41.6%–47.3%) when compared with those with the highest household incomes (36.7%; 95% CI, 33.9%–39.6%). Around two‐thirds of individuals across all assessed weight‐related comorbidities were eligible for GLP‐1RAs under the chronic weight management indication, with eligible adults accounting for 70.3% (95% CI, 66.1%–74.1%) of those with type 2 diabetes, 65.6% (95% CI, 63.5%–67.6%) of those with hypertension and 64.8% (95% CI, 60.6%–68.8%) of those with dyslipidaemia.

TABLE 1.

Characteristics of Australian adults eligible for glucagon‐like peptide‐1 receptor agonist use for chronic weight management.

Characteristics Estimated population, number (95% CI) (thousands, unless otherwise specified) Proportion eligible (95% CI)
Overall d Eligible e Non‐eligible
Unweighted number 13,039 5452 7587 —
Weighted number (millions) 19.7 (19.7 to 19.7) 7.8 (7.6 to 8.1) 11.9 (11.6 to 12.1) 39.7 (38.4 to 41.0)
Age
18–29 years 3813.3 (3696.0 to 3930.6) 841.9 (726.6 to 957.2) 2971.4 (2849.3 to 3093.5) 22.1 (19.4 to 25.0)
30–44 years 5496.4 (5381.1 to 5611.8) 1916.6 (1784.3 to 2048.9) 3579.8 (3425.6 to 3734.0) 34.9 (32.6 to 37.3)
45–64 years 6197.1 (6192.0 to 6202.2) 2874.7 (2735.7 to 3013.7) 3322.3 (3181.6 to 3463.1) 46.4 (44.1 to 48.7)
65+ years 4196.4 (4196.4 to 4196.4) 2188.8 (2113.5 to 2264.0) 2007.7 (1932.4 to 2082.9) 52.2 (50.4 to 53.9)
Sex
Male 9714.5 (9714.4 to 9714.6) 4041.3 (3881.3 to 4201.4) 5673.2 (5513.1 to 5833.2) 41.6 (40.0 to 43.3)
Female 9988.7 (9956.0 to 10021.4) 3780.7 (3624.7 to 3936.7) 6208.0 (6050.0 to 6366.0) 37.8 (36.3 to 39.4)
Clinical history
Type 2 diabetes 1176.7 (1063.4 to 1289.9) 826.8 (741.4 to 912.2) 349.9 (287.2 to 412.5) 70.3 (66.1 to 74.1)
Hypertension 6368.8 (6148.3 to 6589.4) 4175.4 (3990.9 to 4360.0) 2193.4 (2037.0 to 2349.7) 65.6 (63.5 to 67.6)
Dyslipidaemia 2216.3 (2055.1 to 2377.6) 1435.9 (1289.7 to 1582.2) 780.4 (679.0 to 881.8) 64.8 (60.6 to 68.8)
Previous myocardial infarction 434.0 (356.0 to 511.9) 288.1 (224.8 to 351.3) 145.9 (106.5 to 185.3) 66.4 (58.6 to 73.3)
Previous stroke 193.2 (156.6 to 229.8) 113.7 (81.6 to 145.8) 79.4 (53.1 to 105.8) 58.9 (46.8 to 70.0)
Diseases of arteries, arterioles and capillaries 171.2 (129.6 to 212.8) 98.2 (72.8 to 123.7) 73.0 (40.3 to 105.7) 57.4 (44.3 to 69.5)
Other cardiovascular disease a 849.8 (756.2 to 943.4) 545.4 (470.1 to 620.8) 304.4 (248.2 to 360.6) 64.2 (58.7 to 69.3)
Osteoarthritis 2095.7 (1976.0 to 2215.4) 1222.8 (1130.9 to 1314.7) 872.9 (790.4 to 955.4) 58.3 (55.3 to 61.3)
Back pain and other dorsopathies b 3932.8 (3741.0 to 4124.7) 1926.6 (1775.1 to 2078.0) 2006.3 (1889.5 to 2123.0) 49.0 (46.6 to 51.4)
Income c
First quintile (lowest) 2742.4 (2575.7 to 2909.2) 1218.2 (1116.6 to 1319.9) 1524.2 (1396.4 to 1651.9) 44.4 (41.6 to 47.3)
Second quintile 3142.7 (3007.8 to 3277.6) 1453.9 (1356.9 to 1551.0) 1688.8 (1565.6 to 1811.9) 46.3 (43.5 to 49.0)
Third quintile 3539.0 (3358.8 to 3719.2) 1342.4 (1227.5 to 1457.2) 2196.6 (2049.5 to 2343.8) 37.9 (35.3 to 40.6)
Fourth quintile 3994.6 (3738.2 to 4251.0) 1530.0 (1390.3 to 1669.7) 2464.6 (2260.8 to 2668.4) 38.3 (35.5 to 41.1)
Fifth quintile (highest) 4223.3 (4046.9 to 4399.8) 1548.8 (1416.6 to 1681.0) 2674.5 (2505.4 to 2843.7) 36.7 (33.9 to 39.6)
Education
Secondary education or below 7604.2 (7493.3 to 7715.0) 3232.4 (3049.4 to 3415.3) 4371.8 (4218.3 to 4525.2) 42.5 (40.4 to 44.7)
Certificate/diploma 4594.7 (4480.7 to 4708.7) 2030.4 (1915.8 to 2145.1) 2564.3 (2443.2 to 2685.3) 44.2 (42.0 to 46.4)
University‐level education 7037.3 (6903.1 to 7171.5) 2354.9 (2201.4 to 2508.3) 4682.4 (4530.0 to 4834.7) 33.5 (31.5 to 35.5)
Other 467.1 (388.2 to 546.1) 204.3 (159.2 to 249.5) 262.8 (207.2 to 318.4) 43.7 (37.2 to 50.5)
a

Includes angina, other ischaemic heart diseases, other cerebrovascular diseases, oedema and heart failure.

b

Includes back pain or problems, sciatica, disc disorders and curvature of the spine.

c

Total current weekly household income from all sources. A total of 1070 adults did not report total current weekly household income.

d

Includes non‐pregnant adults aged 18 years and older.

e

Includes non‐pregnant adults aged 18 years and older with a body mass index of ≥ 30 kg/m2 or with a body mass index of ≥ 27 kg/m2 to < 30 kg/m2 and at least one weight‐related comorbidity. Excludes adults with type 1 diabetes.

Of the 7.8 million adults eligible for GLP‐1RA use for chronic weight management, 2.9 million (95% CI, 2.7–3.1 million) adults had no weight‐related comorbidities, 3.3 million (95% CI, 3.1–3.4 million) adults had one weight‐related comorbidity and 1.7 million (95% CI, 1.6–1.8 million) adults had at least two weight‐related comorbidities (Figure 1; Table S2). In addition, among those eligible individuals, 1.6 million (95% CI, 1.4–1.7 million) had a BMI between 27.0 and 29.9 kg/m2, 3.8 million (95% CI, 3.6–3.9 million) had a BMI between 30.0 and 34.9 kg/m2, 1.6 million (95% CI, 1.5–1.7 million) had a BMI between 35.0 and 39.9 kg/m2, and 909.0 thousand (95% CI, 805.8–1012.1 thousand) had a BMI of 40.0 kg/m2 or higher. Figure 1 presents the total numbers of eligible adults for each combination of BMI category and number of weight‐related comorbidities. Sensitivity analysis found that 7.0 million adults without type 2 diabetes are eligible for GLP‐1RA use under the TGA indication for chronic weight management (Table S3).

FIGURE 1.

FIGURE 1

Total numbers of adults eligible for GLP‐1RA medications for each combination of BMI category and number of weight‐related comorbidities. BMI, body mass index; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist.

In total, up to 338.9 thousand (95% CI, 271.3–406.5 thousand) Australian adults with overweight or obesity are eligible for GLP‐1RA medications for established cardiovascular disease. Of these, 285.7 thousand (95% CI, 224.4–346.9 thousand) met our definition of confirmed established cardiovascular disease and 53.2 thousand (95% CI, 33.2–73.3 thousand) additionally met our definition of possible established cardiovascular disease (Figure 2; Table S4). In total, 7.5 million (95% CI, 7.2–7.7 million) adults eligible for chronic weight management are not eligible for secondary prevention of established cardiovascular disease. For those adults confirmed as eligible under this indication, 92.0 thousand (95% CI, 56.1–127.8 thousand) had a BMI between 27.0 and 29.9 kg/m2, 119.7 thousand (95% CI, 76.3–163.0 thousand) had a BMI between 30.0 and 34.9 kg/m2, 41.7 thousand (95% CI, 21.7–61.7 thousand) had a BMI between 35.0 and 39.9 kg/m2 and 32.3 thousand (95% CI, 14.4–50.2 thousand) had a BMI of 40 kg/m2 or higher. Figure 2 presents the total numbers of eligible adults with confirmed and possible established cardiovascular disease across BMI categories.

FIGURE 2.

FIGURE 2

Total numbers of adults eligible for GLP‐1RA medications with confirmed and possible established cardiovascular disease across BMI categories. BMI, body mass index; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist.

4. Discussion

This study provides the first published estimates of population‐level eligibility for GLP‐1RA medications in Australia, indicating that under the TGA indications, 39.7% of adults are eligible for chronic weight management and up to 1.7% of adults are eligible for secondary prevention of established cardiovascular disease in individuals with overweight and obesity. Overall, up to 4.3% of those eligible for the chronic weight management indication also meet the criteria for established cardiovascular disease. These figures are slightly lower than those reported in previous studies of other high‐income countries, where about 41.8% of adults are estimated to be eligible to use this class of medications for chronic weight management [11]. In addition, the nationwide estimates of the number of adults meeting the TGA indications under various coverage scenarios provide useful information to healthcare professionals regarding how many patients are potentially eligible for treatment, as well as to policymakers involved in determining criteria for potential subsidies for these medications.

Although 7.8 million Australian adults are potentially eligible for GLP‐1RA treatment under the chronic weight management indication, complete uptake is unlikely. Among key Phase 3 trials of these medications, the rate of treatment discontinuation due to adverse events after 1 year was between 4.0% and 7.1% [15, 16, 17, 18]. Studies using real‐world data have shown higher rates of discontinuation, ranging between 36.5% and 64.8% at 1 year [20, 21, 22], although global shortages affecting GLP‐1RA access during the study periods may have inflated these estimates [23, 24]. Other patient‐reported factors impacting GLP‐1RA adherence or adoption include cost and degree of weight loss [22, 24, 25]. Treatment adoption may also be influenced by provider–patient education or reluctance to prescribe due to concerns regarding clinical suitability or rare adverse effects [22, 26]. In addition, our findings estimate that 827 thousand adults potentially eligible for GLP‐1RA treatment under the chronic weight management TGA indication have type 2 diabetes, and may already be eligible to receive PBS‐subsidised GLP‐1RA treatment.

Despite this, even far lower levels of uptake and successful pricing negotiations with manufacturers would have significant economic implications for federal budgets if GLP‐1RA medications were PBS‐subsidised according to TGA indication criteria. To manage the economic implications of expanding coverage, some high‐income countries have created policies which prioritise access to specific populations [9, 27]. Limiting subsidised access based on an individual's BMI and the presence of weight‐related comorbidities may be one approach to mitigating high costs. Elevated BMI is associated with a higher risk of developing several conditions, including cardiovascular disease and type 2 diabetes [28, 29]. Our findings indicate that limiting coverage to adults with a BMI of ≥ 35 kg/m2 would provide subsidised access to about 2.5 million adults. A further reduction could be achieved by limiting eligibility to adults with a BMI of ≥ 35 kg/m2 and at least one weight‐related comorbidity, resulting in potential subsidised access to an estimated 1.5 million adults. While such approaches may constrain costs, post hoc analyses of the STEP and SURMOUNT trials have suggested that both semaglutide and tirzepatide are effective in reducing body weight across all BMI subgroups ≥ 27 kg/m2 [30, 31]. Moreover, even in the absence of associated chronic diseases, obesity can substantially impair health and function [32].

Importantly, our findings demonstrate that eligibility is not evenly distributed across socioeconomic groups. Nearly 45% of individuals living in low‐income households currently meet criteria for these medications for weight management. While this finding may be influenced by sociodemographic or health‐related drivers, regardless of the underlying cause of such disparities, high out‐of‐pocket costs associated with private prescriptions raise concerns about inequitable access. Without PBS subsidy, the cost of the GLP‐1RA semaglutide, at the recommended maintenance dose of 2.4 mg, is about $460 per person each month [33]. While the recent emergence of generic GLP‐1RAs in countries such as Canada is expected to substantially reduce costs [34], Australian adults not meeting the PBS‐subsidy criteria are expected to face high out‐of‐pocket costs for these medications, with key patents not expected to expire until the 2030s [35, 36]. Prioritising coverage to those at greatest risk of adverse health outcomes, including consideration of social determinants of health, may better facilitate equitable access to these medications. Such an approach would be consistent with recent World Health Organization guidelines which emphasise the urgent need for evidence‐based, equity‐focussed strategies to expand access to these medications for adults with obesity [37]. In addition, it is essential to improve access to allied health support to optimise nutrition, physical activity and behaviour change.

Furthermore, our study suggests that about 338.9 thousand adults would be eligible for semaglutide under its current approval for secondary prevention of cardiovascular disease. Based on recent PBAC recommendations [8], limiting semaglutide eligibility to adults with established cardiovascular disease and a BMI of ≥ 35 kg/m2 would reduce the maximum expected number of adults who could receive subsidised semaglutide to about 88.1 thousand. While this approach aids in reducing total spending, subgroup analysis of the SELECT trial data has shown cardioprotective benefits of semaglutide across all BMI groups ≥ 27 kg/m2, with the largest observed reduction in major adverse cardiovascular events among adults with a BMI of less than 35 kg/m2 [38]. This emphasises the need for caution when limiting coverage based on BMI, as doing so may result in limiting access for patients who are likely to benefit from treatment based on available data from large, randomised trials [7].

4.1. Limitations

This study has several limitations. First, we did not have access to data on obstructive sleep apnoea diagnoses, which is one of the weight‐related comorbidities used to determine eligibility for GLP‐1RAs. Because of this, estimates of the number of people eligible for these medications for weight management with a BMI of less than 30 kg/m2 are likely to be somewhat conservative. Second, the National Health Survey aggregates data on vascular diseases into a broader category of diagnoses related to arteries, arterioles and capillaries (International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes I70–I79). Because of this, we could not specifically identify individuals with symptomatic peripheral arterial disease in our analysis of those eligible for secondary prevention of established cardiovascular disease. However, our analysis classifying individuals with this broader category of vascular conditions as potentially meeting this indication provides an estimate of the upper limit of how many adults may be eligible for GLP‐1RAs for cardiovascular risk reduction. Third, there are several potential contradictions to GLP‐1RA medications that could not be reliably identified with the data available. Fourth, a proportion of survey respondents were missing BMI data derived from physical measurement of height and weight (non‐response, 40.8%). For these participants, we relied upon values imputed by the Australian Bureau of Statistics using established methods based upon self‐reported height, weight and other key predictive factors to provide representative estimates of BMI across the entire survey population [14]. While there may be differences between measured and imputed data, it is unclear to what extent this would have impacted our estimates. Fifth, this study did not include an economic evaluation. Future research should assess budgetary impact and cost‐effectiveness while accounting for factors such as average dose, treatment adherence, cost variation and different subsidy policies. Further to this, evaluation is needed to explore the broader societal implications of these medications, including the impact on productivity and labour force participation.

5. Conclusion

About 7.8 million Australian adults are currently eligible for GLP‐1RA medications according to approved indications for chronic weight management, with up to 338.9 thousand adults also eligible for secondary prevention of established cardiovascular disease. Of note, almost 45% of individuals living in low‐income households are currently eligible to use these medications for weight management, though prohibitive costs for private market prescriptions raise concerns about inequities in access to these effective treatments. Acknowledging that broad PBS‐subsidised access for all eligible adults would pose challenges due to the high cost of treatment, this study provides valuable insight to allow clinicians and policymakers to understand the number of adults in Australia who could potentially access GLP‐1RA medications based on TGA indication criteria and under a range of possible coverage scenarios.

Author Contributions

Jasmin Castrillon: conceptualisation, formal analysis, writing (original draft). Chris Schilling: supervision, conceptualisation, writing (review and editing). Sharmala Thuraisingam: supervision, conceptualisation, writing (review and editing). Michael W. Hii: supervision, conceptualisation, writing (review and editing). Priya Sumithran: supervision, conceptualisation, writing (review and editing). Peter F. Choong: supervision, conceptualisation, writing (review and editing). Michelle M. Dowsey: supervision, conceptualisation, writing (review and editing). Cade Shadbolt: supervision, conceptualisation, writing (review and editing).

Funding

Jasmin Castrillon was supported to conduct this work by an Australian Government Research Training Program Scholarship. No other funding or support was received.

Conflicts of Interest

Chris Schilling reports receiving grants paid to his institution from HCF Research Foundation, Medical Research Future Fund, Victorian Cancer Agency, Eli Lilly, Intuitive Foundation, University of Melbourne, and St Vincent's Hospital Melbourne Research Endowment Fund. Michael W. Hii reports receiving honoraria for lecturing at Pillars of Dermatology Practice Symposium; receiving travel support from Johnson and Johnson to attend a clinical surgical immersion program in Bruges, Belgium; receiving travel support from Medtronic to attend a clinical surgical immersion program in Brisbane, Australia; and being a chairperson for the HOPE Fund. Priya Sumithran reports a National Health and Medical Research Council grant, paid to her institution; reports being a former council member of the Australian and New Zealand Obesity Society (unpaid) and a current member of The Obesity Collective leadership group (unpaid); reports being a co‐author on manuscripts with medical writers provided by Novo Nordisk and Eli Lilly; and payment to her institution for participation in advisory and speaking activities from Novo Nordisk and Eli Lilly. Peter F. Choong reports receiving research support for investigator‐initiated studies from Medacta, Eli Lilly, Medibank Private, HCF Research Foundation, National Health and Medical Research Council and Medical Research Future Fund; receiving royalties from Wolters Kluwer; receiving consulting fees from DePuy Synthes (as a member of surgeon design team), Stryker Corporation, Johnson and Johnson, and Medacta; reports being on the editorial boards of EFORT Open Reviews and Journal of Clinical Medicine; and reports being an international corresponding editor for JAAOS International. Michelle M. Dowsey reports receiving research support for investigator‐initiated studies, paid to her institution, from Medical Research Future Fund, National Health and Medical Research Council, Eli Lilly, Victorian Orthopaedic Foundation, Australian Orthopaedic Association Research Foundation, HCF Research Foundation, University of Melbourne, St. Vincent's Hospital Research Foundation, and Arthritis and Osteoporosis Western Australia; reports receiving payment for providing advice on guideline development to the Royal Australian College of General Practitioners; reports receiving a sitting fee as a member of the Osteoarthritis Clinical Research Group data and safety monitoring board; and reports being a board director of the Australian Orthopaedic Association Research Foundation. Cade Shadbolt reports receiving research support for investigator‐initiated studies, paid to his institution, from Eli Lilly, St. Vincent's Hospital Research Foundation and Medical Research Future Fund. No other disclosures were reported.

Supporting information

Table S1: Summary of 2022 National Health Survey variables used to address Therapeutic Goods Administration indication criteria.

Table S2: Cross‐tabulation of the estimated number of adults eligible for glucagon‐like peptide‐1 receptor agonist use for chronic weight management, by body mass index and number of weight‐related comorbidities.

Table S3: Cross‐tabulation of the estimated number of adults eligible for glucagon‐like peptide‐1 receptor agonist use for chronic weight management without type 2 diabetes, by body mass index and number of weight‐related comorbidities.

Table S4: Cross‐tabulation of the estimated number of adults eligible for glucagon‐like peptide‐1 receptor agonist use for chronic weight management, by body mass index and presence of established cardiovascular disease.

MJA2-224-0-s001.pdf (299.4KB, pdf)

Acknowledgements

Open access publishing facilitated by The University of Melbourne, as part of the Wiley ‐ The University of Melbourne agreement via the Council of Australasian University Librarians.

Data Availability Statement

All statistical code used for this study is available from the corresponding author upon request. The underlying data from the National Health Survey is not publicly available. Requests to access National Health Survey data are managed by the Australian Bureau of Statistics.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table S1: Summary of 2022 National Health Survey variables used to address Therapeutic Goods Administration indication criteria.

Table S2: Cross‐tabulation of the estimated number of adults eligible for glucagon‐like peptide‐1 receptor agonist use for chronic weight management, by body mass index and number of weight‐related comorbidities.

Table S3: Cross‐tabulation of the estimated number of adults eligible for glucagon‐like peptide‐1 receptor agonist use for chronic weight management without type 2 diabetes, by body mass index and number of weight‐related comorbidities.

Table S4: Cross‐tabulation of the estimated number of adults eligible for glucagon‐like peptide‐1 receptor agonist use for chronic weight management, by body mass index and presence of established cardiovascular disease.

MJA2-224-0-s001.pdf (299.4KB, pdf)

Data Availability Statement

All statistical code used for this study is available from the corresponding author upon request. The underlying data from the National Health Survey is not publicly available. Requests to access National Health Survey data are managed by the Australian Bureau of Statistics.


Articles from The Medical Journal of Australia are provided here courtesy of Wiley

RESOURCES